Sangamo BioSciences (SGMO) PT Raised to $35 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Price: $0.18 --0%
Rating Summary:
8 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 46
Rating Summary:
8 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 46
Join SI Premium – FREE
JPMorgan raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $35.00 (from $11.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $220 at BMO Capital
- Neurocrine Bio. (NBIX) PT Lowered to $150 at BMO Capital
- Artisan Partners Asset Management (APAM) PT Lowered at TD Cowen After 'Another Attrition-Driven Miss'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
